This page shows the latest immunosuppressant news and features for those working in and with pharma, biotech and healthcare.
The recommendation is specifically for adult patients with the condition who are eligible for systemic treatment, only if the disease has not responded to at least one systemic immunosuppressant, or if
The treatment is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
The treatment has been accepted for restricted use, and is specifically for those who have had an inadequate response to at least one conventional systemic immunosuppressant, or where such treatment is
Dupixent is a fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Anifrolumab is a selective immunosuppressant that binds to sub-unit 1 of the type I interferon receptor blocking the biologic activity of type I interferons, which are cytokines involved in regulating
The whistleblower case was first brought in 2013 and focuses on marketing activities by Novartis for its immunosuppressant product Myfortic (mycophenolate), antihypertensives Lotrel (amlodipine/benazepril) and Valturna (aliskiren/valsartan), and the
More from news
Approximately 2 fully matching, plus 49 partially matching documents found.
Another deal focused on a novel formulation of an established drug is that between Veloxis Pharmaceuticals and Chiesi for the commercialisation and distribution of LCP-Tacro, an immunosuppressant for kidney transplantation ... 58. †Veloxis
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.